1
Exhibit 10.83
[SEQUANA THERAPEUTICS LETTERHEAD]
January 9, 1998
Xxxxx-Xxxx Xxxxxxx
VP of International Legal Affairs
German Offices
Xxxxxxxxx Xxxxxxx 000
X-00000 Xxxxxxxx
Xxxxxxx
Dear Xx. Xxxxxxx,
COLLABORATIVE RESEARCH AGREEMENT BETWEEN SEQUANA THERAPEUTICS, INC., AND
THE CORANGE INTERNATIONAL LTD. EFFECTIVE JUNE 30, 1995 ("AGREEMENT")
We refer to the Agreement and confirm that it is the mutual agreement of the
parties to amend the Agreement effective January 9, 1998 to delete Section
2.2(ii) in its entirety and replace it with the following:
"Corange or its nominee shall purchase equity securities issued
by AxyS Pharmaceuticals, Inc. ("AxyS") in the amount of
$1,250,000 per year on each annual anniversary of the Effective
Date through February 14, 1999. The securities shall be common
stock of AxyS purchased by Corange or its nominee at a price per
share equal to one hundred thirty-five percent (135%) of the
average closing sale price of AxyS common stock as reported in
the Wall Street Journal for the twenty (20) day period ending as
of the date three (3) business days prior to the date of purchase
of shares for such year."
All other terms of the Agreement remain unchanged.
We are enclosing duplicate copies of this letter. If the above is acceptable to
Xxxxxxx, please have the copies signed on behalf of Corange by a duly authorized
signatory and return one fully signed copy to us for our records.
1.
2
Sincerely,
/s/ Xxx Xxxxxx
Xxx Xxxxxx, Ph.D.
Sr. VP of Research & Development
Accepted this 14 day of January, 1998
Corange International Ltd.
Per: /s/ Xxxxxx Xxxxxxx
---------------------
Title: CEO
-----------------------------
cc: Xxxxxxx Xxxxxxxxxx
Business Development
Boehringer Mannheim
2.
